
University of Basel

Faculty of Medicine

European Center of Pharmaceutical Medicine

DAS in Pharmaceutical Medicine
MAS in Medicines Development

2027–2029



ECPM®

European Center of Pharmaceutical Medicine

CONTINUING EDUCATION

Table of Contents

Invitation	3
Lifelong Learning	4
Advance your career	8
ECPM Course and Modules	10
Module 1: Global Drug Development and Pharmaceutical Business Environment	11
Module 2: From Non-Clinical Testing to First-in-Human	12
Module 3: Planning, Collecting and Managing Clinical Data	13
Module 4: Clinical and Safety Data Evaluation and Biostatistics	14
Module 5: Global Registration and Approval Process	15
Module 6: Integrated Product Development, Healthcare Marketplace and Marketing	16
Teaching Framework	18
About ECPM	20
Administrative Information	21
Apply for your postgraduate degree	22

Under the auspices of
EUCOR the European Campus
IFAPP, International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine
Accredited by SwAPP, Swiss Association of Pharmaceutical Professionals and SGPM, Swiss Association of Pharmaceutical Medicine
Recognized as PharmaTrain Centre of Excellence

Invitation

The European Center of Pharmaceutical Medicine (ECPM) is dedicated to being Europe's leading university institute for medicines development. Established in 1991, ECPM was founded to meet the educational needs of specialists in medicines and medical device development. Part of the Department of Public Health of the Medical Faculty at the University of Basel, ECPM collaborates globally and is accredited as an IMI PharmaTrain "Centre of Excellence". It is also recognized by the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) and their respective national associations.

We offer a range of training programs designed to provide a comprehensive understanding of medicines and device development processes – from discovery to bedside. Our curriculum is continuously updated to reflect the latest and future trends of scientific developments, thanks to our distinguished international faculty.

Our training focuses on advanced studies and continuing professional development (CPD). In conformity with the Bologna system, our programs include a Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine and a Master of Advanced Studies (MAS) in Medicines Development. Completing the DAS degree qualifies for specialization recognition by the Swiss Associations of Pharmaceutical Physicians/Professionals (SwAPP/SGPM).

Our programs are tailored for representatives from the pharmaceutical industry, academia, and government decision and policy makers who already possess a good understanding of the basics of drug development. Participants will gain an in-depth, comprehensive and systematic immersion into modern clinical trial management and device development, regulation, and market introduction.

ECPM training programs offer the flexibility to balance full-time work and study, engage with experts, deepen your knowledge, expand your expertise, and build a professional network aligned with your career plan.

An international faculty of experts from academia, pharmaceutical and biotechnology companies, and regulatory authorities carry the teaching responsibility.

We cordially invite you to participate in the ECPM course and very much look forward to meeting you!



Prof Thomas D. Szucs
Director



Dr Annette Mollet
Head of Education & Training




Noah Murer
Course Director

LifeLong Learning
Deepen your expert knowledge and build an international network

Workplace of students

(2025 – 2027)



Small to Medium-Sized Pharma	24%
Big Pharma Top 20	47%
CROs, Expert Services	3%
Regulator	3%
Hospitals	10%
Venture Capital	1%
Academia	5%
Biotech	7%
Total	100%

Mission

Our mission is to create the leading international training platform that enhances the knowledge, expertise and skills required to perform modern discovery, development, regulation and marketing of medical products. Our outstanding faculty integrates cutting-edge concepts and best practices to enable the development of efficient, economical, high-quality and safe medical products for the benefit of the patients and society. We are committed to constant innovation, offering Swiss excellence combined with a global perspective.

Definition of Pharmaceutical Medicine

The International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine defines Pharmaceutical Medicine as "the scientific discipline for the discovery, development, evaluation, registration, monitoring, and medical marketing of medicines for the benefit of the patients."

Target Audience

Our programs are tailored for representatives from the pharmaceutical and service industries, academia, and government decision and policy makers who already possess a good understanding of the basics of drug development. Participants will benefit from a comprehensive, in-depth exploration of modern medical product and device development, regulation, and market introduction.

Syllabus: IMI PharmaTrain

Training in Pharmaceutical Medicine covers all aspects of pharmaceutical medicine and medicines development sciences with an international scope as defined by the PharmaTrain syllabus. This includes the discovery and development of new medicines, biopharmaceutical sciences, clinical pharmacology and trial methodology, good clinical practice and ethics, pharmacovigilance and epidemiology, biostatistics, regulatory affairs, health economics, project and portfolio management, marketing, and new therapeutic approaches.

For details, please see www.pharmatrain.eu/pharmatrain-syllabus or ecpm.ch/education-training/syllabus

Learning Outcomes

On successful completion of training in pharmaceutical medicine, students will understand and be able to:

- Describe the end-to-end drug development process and explain how to apply modern biopharmaceutical development strategies, methods, and tools to improve decision-making.
- Outline the principal steps in drug discovery, including target identification, and summarize the objectives and outputs of non-clinical research.
- Identify and discuss the key scientific, operational, ethical, and regulatory issues involved in undertaking clinical research and development.
- Compare how medicines are regulated in major global markets, including the ethical and legal provisions that govern them.
- Apply principles of pharmacovigilance to manage drug safety issues both pre-authorization and post-authorization.
- Demonstrate understanding of how to manage medicinal product lifecycle activities, including both regulatory and marketing responsibilities.
- Use health economics principles to evaluate and support decisions related to the development and marketing of medicinal products.

Postgraduate Training

Our postgraduate programs provide professionals with opportunities to learn from leading experts,

expand their international networks, and combine academic development with their professional careers. By connecting theoretical knowledge with practical, real-world experience, these programs support the continuous development of knowledge, skills, and competencies. This approach reflects the European Commission's definition of lifelong learning as "all learning activity undertaken throughout life that serves to improve knowledge, skills, and competence."

Following the completion of a bachelor's or master's degree, students can pursue two levels of postgraduate qualifications. The Diploma of Advanced Studies (DAS) makes up the first level of training and comprises 30 ECTS credits. The second and highest level is the Master of Advanced Studies (MAS), which requires a minimum of 60 ECTS credits.

Together, these qualifications offer a flexible pathway for professionals seeking to deepen their expertise, strengthen their professional competencies, and advance their careers through lifelong learning.

Graduates

DAS

since 2001

714

MAS

since 2015

13



Biozentrum Basel, exterior view


Unique Program Features

- Build comprehensive expertise in pharmaceutical medicine and gain a deep understanding of the entire medical product lifecycle—from molecule to marketplace—while continuing to work full time.
- Stay ahead of emerging trends in global pharmaceutical development and the evolving healthcare landscape.
- Learn from leading experts from industry, academia, and regulatory authorities, gaining valuable insights from different perspectives across the field.
- Explore innovative methods, tools, and strategies and apply them directly to your professional practice.
- Develop core leadership skills to effectively contribute to and drive medical product development across disciplines.
- Build a global professional network and strengthen your capabilities for your next career step.
- Enhance your professional profile by earning a university issued Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine, or advance to a Master of Advanced Studies (MAS) in Medicines Development.
- Obtain recognized professional qualifications, including Swiss specialty recognition for physicians (MDs) or a SwAPP Diploma.

University of Basel

The University of Basel is Switzerland's oldest university and has been educating talents since 1460. Leading higher-education rankings such as the "Academic Ranking of World Universities" consistently place the University of Basel among the world's 100 best universities with its Medical Sciences faculty ranked 75th. Life Sciences are the main focal area at the University of Basel, closely linked with Basel's status as a center of pharmaceuticals and biotechnology.

The ECPM training platform



Postgraduate title system: The first level [L1] represents the Diploma of Advanced Studies in Pharmaceutical Medicine including six mandatory basic modules (DAS 30 ECTS). The diploma can be supplemented on a second level [L2] with CPD short courses and a thesis to achieve a Master of Advanced Studies [L3] (60 ECTS). The diploma also covers the theoretical requirements to apply for the Swiss specialist title in pharmaceutical medicine.




Biozentrum Basel, entrance hall

Advance your Career
by earning a postgraduate title in Pharmaceutical Medicine

Educational background of students

(2025 – 2027)



MD	29%
MD PhD	9%
MBA, MA Economics	8%
PhD Biotechnology	13%
PhD Pharmacy	8%
PhD Chemistry	7%
MSc Biology	4%
MSc Chemistry	3%
MSc Pharmacy	4%
MSc Life Science	4%
MSc Communication	3%
BSc Biology	3%
MSc Veterinary	1%
MSc MD	3%
BSc Chemistry	1%
Total	100.0%

Overview of the Postgraduate Titles

In conformity with the Bologna system, two postgraduate degrees are offered. We believe that in-person interaction provides the best learning experience, which is why we conduct the majority of our diploma courses onsite.

Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine – 30 ECTS

To achieve a Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine from the University of Basel, participants must successfully complete a two-year course cycle and pass a multiple choice questions (MCQ) exam, along with an oral and an essay exam. The oral exam involves discussing a peer-reviewed paper provided in advance. The essay exam requires writing three one-page summaries on specified topics.

Master of Advanced Studies (MAS) in Medicines Development – 60 ECTS

To earn a Master of Advanced Studies (MAS) in Medicines Development from the University of Basel, participants must fulfill the following requirements:

- Successfully complete the DAS (30 ECTS), additional selected master modules from the Continuing Professional Development (CPD) short courses program (20 ECTS) and write a master's thesis (10 ECTS).
- Students have the option to enroll in both the ECPM course and the MAS program concurrently. The total duration of study should not exceed five years.

The additional master modules related to drug development sciences and aligned with the IMI PharmaTrain syllabus may be selected according to individual interest and professional needs. Students may choose from ECPM courses or from other recognized course providers and partner universities. Students are strongly encouraged to consult with the ECPM course directorate in advance to confirm that courses offered by external institutions can be formally accredited toward the program.

The master's thesis topic should ideally relate to the candidate's professional field, area of expertise or particular academic interest. Participants may propose their own topic or develop one in consultation with the course directorate. Once all prerequisites have been fulfilled, the thesis may be commenced at any time. The final thesis may be submitted as a written report of up to 40 pages or as a manuscript prepared for submission to a peer-reviewed scientific journal. Participants are encouraged to complete the thesis within two semesters.

Swiss Specialist in Pharmaceutical Medicine (FMH and SwAPP)

Participants who successfully complete the DAS may pursue a recognized professional qualification in Pharmaceutical Medicine.

- Physicians (MDs) may apply for the Swiss Specialist in Pharmaceutical Medicine Diploma awarded by the FMH, Swiss Association of Medical Doctors – (www.sgpm.ch)
- Graduates holding an MSc or PhD may apply for the SwAPP Diploma awarded by the Swiss Association of Pharmaceutical Professionals – (www.swapp.ch)

Certificate of Advanced Studies (CAS)

New Certificates of Advanced Studies in Pharmaceutical Medicine are currently being developed and will be announced in due time.

Attendance and Examination

A minimum attendance rate of 80% is required to be eligible to sit the examinations and to obtain a degree from the University of Basel. The final examinations are conducted as a closed-book test, on iPads and take place onsite at the university campus. Participants completing the DAS may choose to take all three examinations on a single day or distribute them over two days. For participants pursuing the FMH title, the examination must be completed on two separate days.

The Bologna Process and the European Higher Education Area

The Bologna Process, initiated in 1999, is an intergovernmental framework for higher education involving 49 European countries. Its primary objective is to promote greater coherence and compatibility among higher education systems across Europe. The European Higher Education Area (EHEA) aims to facilitate the mobility of student and academic staff, strengthen cooperation among education institutions and enhance the attractiveness and global competitiveness of European higher education.

European Credit Transfer and Accumulation System (ECTS)

The European credit transfer and accumulation system (ECTS) is a learner-centered framework for the accumulation and transfer of academic credits. It is based on transparency in the learning, teaching, and assessment processes and supports consistency and comparability across European higher education.

ECTS credits reflect the workload required to achieve defined learning outcomes. 1 ECTS equals 30 student investment hours.

	DAS	Swiss Specialist in PM or SwAPP Diploma	MAS	CPD
6 Diploma Modules	■	■	■	□
MCQ Examination	■	■	■	□
Oral/Essay Examination	■	■	■	□
Single or Individual Stand-Alone Modules	□	□	■	■
Master's Thesis	□	□	■	□
Practical Work Experience	□	■	□	□
ECTS Credits	30	30	60	1–5
Results in Title	Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine	Specialist Title → Application with Professional Association	Master of Advanced Studies (MAS) in Medicines Development	Certificate of Attendance

ECPM Course and Modules
From molecule to marketplace

Course Structure

The ECPM course program is structured to provide a balance between academic learning, practical application and professional development. It consists of:

- Six modules, each lasting four days over a two-year period
- 24 days of face-to-face teaching, complemented by examinations
- Course schedule: Monday through Thursday
- Interactive case studies involving teamwork
- Approximately eight hours of pre-reading for each module
- Course language: English.

1. ECPM Course Modules
The ECPM course provides a comprehensive foundation of the fundamentals of drug development. Participants acquire essential knowledge and develop an understanding of the key scientific, clinical, regulatory and strategic aspects involved in bringing medical products from discovery to the market.

2. Continuing Education Seminars – "Frontiers in Drug Development"
The first three days of each ECPM course module focus on the fundamentals of drug development. The fourth day is dedicated to the "Frontiers in Drug Development" seminar, which addresses emerging trends, innovation and current developments in drug development science.

The "Frontiers in Drug Development" seminar can also be attended independently as part of continuing professional education. It is open to ECPM alumni as well as other interested participants seeking to stay informed about the latest advances in drug development.

Diploma Course Cycle 2027–2029

Module 1	Global Drug Development and Pharmaceutical Business Environment	September 6–9, 2027
Module 2	From Non-Clinical Testing to First-in-Human	February 7–10, 2028
Module 3	Planning, Collecting and Managing Clinical Data	June 26–29, 2028
Module 4	Clinical and Safety Data Evaluation and Biostatistics	September 4–7, 2028
Module 5	Global Registration and Approval Process	February 5–8, 2029
Module 6	Integrated Product Development, Healthcare Marketplace and Marketing	June 18–21, 2029
Final Examination	Multiple Choice	August 21, 2029
	Oral / Essay	September 12, 2029

September 6–9, 2027

GLOBAL DRUG DEVELOPMENT AND PHARMACEUTICAL BUSINESS ENVIRONMENT

Content

The pharmaceutical industry is characterized by long development timelines, high research and development costs, patent protections, and a complex regulatory environment. Companies operate in a global marketplace, navigating different regulatory standards, market needs, and healthcare systems.

Principles and future trends of global pharmaceutical research and development, including implications for drug selection, and regulatory and business evaluations. The role of patenting new chemical and biological compounds and the innovation in discovery and development as a response to medical and market needs.

Key topics

- Discovering, modifying, assessing and patenting new chemical and biological compounds
- Systems biology and principles of translational research
- Target identification and validation
- Introduction to the drug development process
- Key stakeholders in the healthcare system
- Design and structure of different healthcare systems
- Project and portfolio management techniques

Learning outcomes

At the end of this module, students should be able to outline the:

1. Principal discovery and validation steps in drug development
2. Elements, functions and management involved in translational research and integrated development of a new drug
3. Principles of patenting new chemical and biological compounds
4. Principles of balancing a pharma portfolio



1

Module 1



Jasmina Huber, PhD

Specialist in the Medicinal Product Licences and Surveillance Sector, Swissmedic, Switzerland

« I was looking out for further training in the medical field – because it interests me and we can use the know-how in our Division. I came across the Diploma of Advanced Studies in Pharmaceutical Medicine at the Medical Faculty of the University of Basel – my manager Magali Gobet was likewise enthusiastic. The course lasts for two years and, with regard to content, it fits the bill perfectly. It will give me an insight into the world of clinical studies and everything that is needed – from the development to the marketing of new therapeutic products. This knowledge will be valuable not only for our Division but also beyond, as cross-divisional cooperation is essential at Swissmedic. »

2

Module 2

February 7–10, 2028

FROM NON-CLINICAL TESTING TO FIRST-IN-HUMAN

Content

Prioritization of areas of therapeutic interest and the development of the target product profile. Principles for target identification, understanding of combinatorial chemistry and druggability of new compounds. Exploring possible new drugs through preclinical safety and efficacy testing. The choice and the predictive value of animal testing for toxicity data as well as the principles of ADME, possibilities and opportunities of computer-assisted modeling on the way to proof of concept. Pharmaceutical engineering and choice of formulation.



Key topics

- Non-clinical testing for chemical and biological compounds, including pharmacology (ADME) and toxicology
- Development, testing and formulation of chemical and biological compounds
- Non-clinical testing requirements prior to First-in-Human studies
- Molecular and cellular basis of toxicological reactions
- Genetic and genomic factors in drug development and drug response
- Transition from non-clinical to First-in-Human studies
- Clinical pharmacology and application to clinical development

Learning outcomes

At the end of this module, students should be able to outline the:

1. Value and specifications of non-clinical testing programs and their integration into the overall drug development plan
2. Safety and efficacy considerations
3. Principles of clinical pharmacology and their application to clinical development
4. Impact of genetic predisposition
5. Requirements, planning and regulations of non-clinical and First-in-Human studies



Heiko Visarius, PhD

CEO, VISARTIS Healthcare GmbH, Switzerland

« Teaching at ECPM lets me bring the start-up and innovation perspective directly into the world of pharmaceutical medicine – showing participants how an idea actually becomes a product, a company, and eventually a patient benefit. What strikes me every year is the caliber of the exchange: professionals from industry, regulatory bodies and academia challenging each other's assumptions in the room. I always leave having learned as much from the participants and fellow faculty as I hope they took from me. »

June 26–29, 2028

PLANNING, COLLECTING AND MANAGING CLINICAL DATA

3

Module 3

Content

The planning and choice of different trial designs, randomization modes and of endpoints. The different aspects of the conduct of a trial, e.g., study monitoring, principles of good clinical practice (GCP), adverse event monitoring (risk/benefit assessment) and data management are demonstrated. Basic principles of biostatistics and its application in superiority and non-inferiority trials. Clinical trial registries and data transparency.

Key topics

- Early studies in volunteers and patients: dose-finding/proof-of-concept or mechanism studies
- Confirmatory clinical development plan
- Different types of clinical studies, including superiority and non-inferiority trials
- Planning and managing clinical trials
- Clinical trial registries
- Legal requirements and Good Clinical Practice (GCP) in the clinical trial process
- Statistical considerations in the design of clinical trial protocols and analysis of clinical trial data
- Patient involvement

Learning outcomes

At the end of this module, students should be able to outline the:

1. Management of early studies in patients and their impact on the drug development plan
2. Principles and practical relevance of ethical and legal issues in biomedical research
3. Design of various types of clinical studies and statistical methods used
4. The confirmatory clinical development plan including the role of relevant study committees
5. Key issues in conducting clinical trials and the role of clinical trial registries





Thomas Brookland, MSc

Regulatory Science Policy Leader, Roche, Switzerland

« It has always been a true privilege and pleasure to join the ECPM faculty as a guest lecturer in this course by sharing insights on pharmaceutical innovation. Drug and device development is a vital, rapidly evolving, and uniquely complex industry, making in-depth education in this space immensely valuable. I am always deeply impressed by the caliber of the students – their engagement and questions always make for a fantastic dynamic – and I have the utmost respect for the esteemed faculty who continue to deliver such an essential course. My only regret in 20 years in the industry is that I never got to take this course myself! »

4

Module 4



Kenneth Kaitin, Prof.

Professor of Medicine, Tufts University School of Medicine, and Senior Fellow, Center for the Study of Drug Development, Tufts University, USA

« The economic, regulatory, scientific, and technology landscape for drug development is constantly evolving. For life-science professionals seeking to build or advance a career in the pharmaceutical sector, understanding these challenges is vital. ECPM offers a unique opportunity to develop that understanding through a comprehensive curriculum covering all aspects of pharmaceutical medicine. Taught by distinguished experts from industry, academia, regulatory authorities, and consulting, the program provides diverse perspectives and real-world expertise to create a highly stimulating, rigorous, and rewarding learning environment. »

September 7 – 10, 2028

CLINICAL AND SAFETY DATA EVALUATION AND BIOSTATISTICS

Content

Advanced methods of biostatistics and application of different trial designs, within-trial decisions, data management, extraction, manipulation and storage of data. Clinical trial protocol design and final report. Procedures and databases for pharmacovigilance and pharmacoepidemiology surveillance, risk management plans.

Key topics

- Development of a clinical trial protocol and the investigator drug brochure (IDB)
- Legal and ethical provisions for protection of clinical trial subjects



- Statistical methods used in clinical research
- Evaluation and interpretation of clinical trial results
- Introduction to Pharmacovigilance and Pharmaco-Epidemiology
- Collection and evaluation of adverse event data in clinical trials, data and safety monitoring board

Learning outcomes

At the end of this module, students should be able to outline the:

1. Development of a clinical trial protocol and the role of the investigator drug brochure (IB)
2. Evaluation and interpretation of clinical trial results
3. Main statistical methods used in clinical data analysis
4. Collection and evaluation of adverse event data in clinical trials
5. Pharmacovigilance and risk management concepts

February 5–8, 2029

GLOBAL REGISTRATION AND APPROVAL PROCESS

5

Module 5

Content

Overview of mechanisms and regulatory management systems in Europe, the USA and other representative countries. Requirements of a regulatory application, documentation and collaboration between developers and regulators. Special regulatory procedures for rare diseases and vulnerable populations, regulatory strategies and crisis management. Product information regulation and summary of product characteristics. Medical devices and combination products.

Key topics

- Pre- and post-approval regulation of medicines at the EU and global level
- Regulatory activities and strategy within a pharmaceutical company
- Summary of product characteristics and labeling requirements
- National and international bodies responsible for medicines regulation and their procedures
- Off-label/unlicensed use of medicines
- International Council for Harmonisation (ICH)
- Preparation and submission of marketing application, common technical document (CTD)
- Communication with regulatory authorities

Learning outcomes

At the end of this module, students should be able to outline the:

1. General principles of medicines and medical devices regulation (both pre- and post-approval)
2. The procedures of the most important regulatory authorities worldwide
3. Preparing necessary documents for drug registration/marketing authorization
4. Regulatory procedures and strategies for rare diseases and vulnerable populations





Adnan Osmani, MBA

Head of Process Analytical Science, Novartis, Switzerland

« In today's complex pharma landscape, true leadership requires connecting the dots across the entire value chain. Working in TRD, I see firsthand that mastering the lifecycle end-to-end – bridging discovery research, technical development, clinical operations, and global commercialization – is essential for impactful decision-making. ECPM delivers exactly this comprehensive perspective, deeply embedding cutting-edge AI, data and digital innovation, with patient outcomes always at the center of care. The program flawlessly integrates all developmental steps, regulatory frameworks, and healthcare systems, while the diverse global network provides a cross-functional exchange that profoundly sharpens your strategic horizon. »

6

Module 6



André Vicente, MD

Lead Medical Director
Roche, Switzerland

« As an MD pursuing the Swiss Specialist in Pharmaceutical Medicine title (FMH), the ECPM program has been an absolute game-changer for my career. The course offers a brilliantly structured, comprehensive deep dive into the entire medical product lifecycle, seamlessly bridging complex theoretical concepts with practical, real-world application. What truly sets ECPM apart is the unparalleled caliber of its international faculty and the interactive case studies that provide insights I can instantly apply to my daily work. Furthermore, the diverse backgrounds of my peers created an exceptional networking environment that enriched every single discussion. ECPM not only perfectly fulfilled the theoretical requirements for my specialist training but profoundly elevated my strategic thinking and leadership skills in global drug development. I wholeheartedly recommend this outstanding program to anyone looking to make a lasting impact in the healthcare and pharmaceutical sector! »

June 18–21, 2029

INTEGRATED PRODUCT DEVELOPMENT, HEALTHCARE MARKETPLACE AND MARKETING

Content

Principles of project and portfolio management, including aspects of planning, project valuation and decision making. How to successfully place a new drug on the market. Principles of health economics, market access, health technology assessment and reimbursement strategies. Life cycle management. Mergers and acquisitions.



Key topics

- Principles and regulations of drug marketing
- Good Promotional Practice: ethical and legal principles pertaining to marketing activities
- Health economics and health technology assessment (HTA)
- Life cycle management
- Strategic considerations of portfolio management
- Mergers and Acquisitions

Learning outcomes

At the end of this module, students should be able to outline the:

1. Drug lifecycle activities and management
2. Market access and marketing of a drug
3. Principles and practical application of health economics, health technology assessment (HTA), pricing and reimbursement
4. Value of mergers and acquisitions



Art work at Biozentrum representing the Pharmahub Basel



Sindhiya Jan, PhD

Director Global Clinical Development and Infectious Diseases, AstraZeneca, Great Britain

« With extensive experience in clinical development and medical affairs, I joined ECPM to broaden my perspective and further strengthen my ability to lead increasingly complex global development programmes. The programme fitted seamlessly alongside my demanding role, providing insights that I could apply immediately to strategic and cross-functional challenges. Its expert faculty, practical case studies and international cohort challenged my thinking and deepened my understanding of the medicines development lifecycle. ECPM enhanced my ability to lead across diverse disciplines, navigate complexity and make more integrated strategic decisions. More than a course, it was an inspiring international learning and networking experience. »

Teaching Framework
Combine onsite training with the online learning platform



Lada Leyens, PhD
Senior Director
Regulatory, Takeda,
Switzerland

« It is a huge pleasure to have been part of the ECPM faculty for the past 5+ years. What makes the ECPM program unique in its nature is the combination of academic and industry experts that bridge between the theoretical imperatives in medicines development and the practical applications in the field, always maintaining a pulse on what is most relevant. The participants come from a variety of backgrounds and stakeholders, which enriches the program as they bring very good input often thinking outside of the box from their respective areas. I really recommend this course for anyone wanting to learn end-to-end drug development with very applicable content to your future career development. »

Teaching Principle

The ECPM course follows the IMI PharmaTrain Syllabus for postgraduate education in Pharmaceutical Medicine and aims for the highest academic standard based on Bloom's Taxonomy of Educational Objectives. The learning process includes didactic teaching and places great emphasis on interactive participation. Each module includes the following activities:

Lectures
Selected faculty from industry, academia and regulatory authorities provide state-of-the-art lectures spanning the basics of drug development as well as current trends in important drug, diagnostic and therapeutic areas and related issues.

Lectures focus on interactive learning, in-depth discussions and break-out groups, where participants work on case studies that complement the lectures in each module. To ensure that the curriculum is aligned with trends in pharmaceutical medicine, ECPM continuously consults with an advisory board of external specialists and experts from relevant fields.

Case Studies
Participants work in small interdisciplinary teams on real-life cases. They analyze and discuss problems with faculty members and develop strategies that they then present and defend in a roundtable discussion. Documents and background literature of the case studies are provided prior to each course module. Students are expected to read these materials in advance to facilitate active participation in the discussion.

Gray Book
A notable feature of the course is the online availability of the "Gray Book" authored by Dr. Julian Gray. This book summarizes key aspects of the PharmaTrain syllabus covering the entire drug development process. A print version is also available for our students to purchase.

Frontiers in Drug Development Seminars
The Frontiers in Drug Development Seminars take place on day four of each course module. They are an integral and mandatory part of the ECPM course.

Teaching Evaluation

The University of Basel uses evaluation software that anonymizes student feedback. This input is highly valued as it helps us maintain high-quality education and identify areas for improvement.

Course Material

All students receive electronic access to the teaching materials a few days before each ECPM course module via our Learning Platform.

Access to the online version of the Gray Book is provided through the Learning Platform, with a print version available for CHF 150.

Participants

The majority of our students have a higher degree, such as an MSc, MD, PhD, PharmD, etc. and three to five years of relevant work experience gained in the pharmaceutical and biotech industries or service industry (e.g. consultancy, CROs), in clinical research or while working for governmental policymakers in integrated medical product development, regulation and market introduction fields.

Participants of the ECPM course represent many different countries and working places worldwide. This variety of backgrounds offers a great opportunity to network and learn from your peers.




Venue of the ECPM course – main auditorium of the Biozentrum, University of Basel.

About ECPM

The leading university institute for Pharmaceutical Medicine for over 30 years

Teaching Faculty

(2025 – 2027)



Big Pharma	31%
Small and Medium-Sized Enterprises	9%
CRO	7%
Regulatory Authorities	20%
Academia/ University Hospitals	23%
Consultants	9%
Total	100%

About ECPM

The European Center of Pharmaceutical Medicine (ECPM) or Institute of Pharmaceutical Medicine is dedicated to being the leading university institute for medicines and drug development in Europe. ECPM belongs to the Department of Public Health of the Medical Faculty at the University of Basel and operates with partners worldwide. The institute was founded in 1991 to cover the training needs of specialists working in drug development. It comprises an education and training department and a research department (est. 2003). The ECPM course was established in partnership with EUCOR, the European Confederation of the Upper Rhine Universities Medical Schools of the Universities of Basel, Freiburg i. Br. and Strasbourg, together with the pharmaceutical industry. The professorship in Pharmaceutical Medicine was inaugurated in 2009.

International Network

Between 2009 and 2014, ECPM managed a project under the public-private partnership of the Innovative Medicines Initiative (IMI), focused on education and training in medicines development. The project's achievements include a shared training syllabus, shared examination standards, and mutual recognition of learning outcomes and credit points (see www.pharmatrain.eu).

ECPM established an international network and collaboration with courses in drug development and regulatory sciences. Partner courses at the Peking University Research Institute and the University of San Francisco Hub in Washington, DC share the same teaching principles and quality label. This unique global collaboration offers the possibility to transfer between the sister courses in Basel, Beijing or Washington, DC.

Teaching Faculty

ECPM's teaching faculty consists of over 150 international experts in regulatory sciences, medical product discovery and development, product evaluation and business practices. Lecturers and tutors are drawn from academia, regulatory agencies (such as EMA, FDA and local agencies), pharmaceutical, diagnostic and biotechnology industry, coverage and reimbursement entities, professional societies and national institutes.

Advisory Board

ECPM's advisory board comprises key stakeholders in medicines development from academia, the pharmaceutical industry, regulatory authorities, the ECPM teaching faculty, EUCOR medical schools and other partner universities. This board serves as a critical sounding board and think tank, reviewing results annually and advising on strategies to keep ECPM's training and research aligned with the latest trends and developments and customer and market needs.

Join us on LinkedIn:

Administrative Information
Welcome to the PharmaHub of Basel!

Tuition Fees DAS

Course tuition fee:
CHF 15'750

The tuition fee includes access to the online Learning Platform, the Gray Book (online version), lunches, coffee breaks, one networking event per module, and the multiple choice questions (MCQ) exam fee.

Additional Costs:
Print version of the Gray Book: CHF 150
Oral/essay examination (Diploma of Advanced Studies): CHF 750 (non-refundable)

Tuition, or the first installment, is due upon confirmation of attendance, at the latest by June 30, 2027. Payment can be made in two installments (June 30, 2027, and June 30, 2028).

Additional examinations and examination fee for the specialist title are handled by the respective organizations: SGPM and SwAPP.

Tuition Fees MAS

ECPM DAS course (6 modules; 30 ECTS):
CHF 15'750

Oral/essay examination (Diploma of Advanced Studies): CHF 750 (non-refundable)

Master Modules (20 ECTS): Fees depend on course provider

Master's Thesis, Final Exam, and Master Diploma (10 ECTS): CHF 3'500

You may register for the master's degree at any time after starting the ECPM course, with a maximum study duration of five years.

	DAS	Swiss Specialist in PM or SwAPP Diploma	MAS	CPD
6 Diploma Modules	15'750	15'750	15'750	
Gray Brook (optional)	150	150	150	
MCQ Examination **Retake**	– 500	– 500	– 500	
Oral/Essay Examination **Retake**	750 750	750 750	750 750	
Single or Individual Stand Alone Modules	na	na	750 – 3000 course dependent	750 – 3000
Master's Thesis			3'500	
Total	16'500	16'500 plus registration with professional association	about 25'500 depending on choice of modules	na

Tuition fees in CHF

Nationalities of students
(2025–2027)
21

Number of students
(1991–2027)
2305

Apply for your postgraduate degree in Pharmaceutical Medicine



Sarah Thiele
Course Coordinator

Admission Criteria

To enroll in the ECPM course, applicants must hold a higher university degree such as a master's, MD, PharmD or PhD. This postgraduate program is designed for professionals in the pharmaceutical industry, regulatory agencies, and academia who seek to enhance their expertise. Ideal candidates will have a primary interest in medical product discovery, development, regulation and healthcare systems. Candidates should also have at least one year of relevant work experience in the drug development process.

Applications that do not meet these criteria can be considered on an individual basis.

Application Dossier

To apply please submit the following via the registration link on the ECPM website:

- A one to two-page curriculum vitae
- A copy of your university diploma (or a certified English or German translation)

Applications are reviewed by the course directorate on an ongoing basis. As enrollment is limited, early application is encouraged.

A strong command of English (C1 level) is required to effectively engage with course material. While formal language certificates are not required, applicants must ensure they possess the necessary proficiency for lectures, discussions, and written assignments.

Registration

Please register online at ecpm.unibas.ch/DAS for the ECPM course.

For the Master of Advanced Studies, please register at ecpm.unibas.ch/MAS.

If you have questions regarding your registration, please do not hesitate to contact Sarah Thiele at ecpm@unibas.ch.

Deadline for Registration

The next ECPM course cycle begins in September 2027 and concludes in June 2029. The registration deadline is June 30, 2027.

If places are still available, applications may be accepted after the deadline has passed.

Registration as Student of the University of Basel

Participants will be registered as students at the University of Basel. A separate form for the student card will be provided by the university, and student registration is included in the tuition fee.

Cancellation Policy

- Cancellations made at least four weeks before the course start date (by August 9, 2027) will receive a 100 % refund.
- Cancellations made in writing within four weeks of the start date (after August 9, 2027) will incur a CHF 750 administrative fee.
- Cancellation requests made after the course begins will not receive a refund.
- Participants who do not attend on the scheduled dates will be invoiced for the full course fee.

Course Venue

The course will take place on the campus of the University of Basel.

Travel and Accommodation

Participants should book their own travel arrangements and hotel rooms.



Coffee break and networking.



Participants of the 18th ECPM Course Cycle (2025–2027).

Imprint

Published by
ECPM
Institute of
Pharmaceutical Medicine
Klingelbergstrasse 61
4056 Basel
Switzerland
www.ecpm.ch

Photography:
Page 3:
© Ursula Sprecher, Basel
Page 7, 17, 19, 23:
© Samuel Bosshardt, Basel
Page 5:
© Atelier Fontana, Basel
Page 1: AI
Page 11, 12, 13, 14, 15, 16: shutterstock

Design Concept and Layout:
atelier w, Basel

All rights reserved. Copies and reproduction of any kind require the permission of the editor.

Educating
Talents
since 1460.

University of Basel
ECPM
Institute of Pharmaceutical Medicine
Klingelbergstrasse 61
4056 Basel
Switzerland

www.ecpm.ch